HDACi-4b

CAS No. 537034-15-4

HDACi-4b ( NKL22;NKL-22 )

Catalog No. M14906 CAS No. 537034-15-4

A benzamide-type HDAC inhibitor with IC50 of 78 uM for changes of FXN mRNA in affected GM15850 cells.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 27 In Stock
10MG 42 In Stock
25MG 87 In Stock
50MG 165 In Stock
100MG 318 In Stock
500MG 752 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    HDACi-4b
  • Note
    Research use only, not for human use.
  • Brief Description
    A benzamide-type HDAC inhibitor with IC50 of 78 uM for changes of FXN mRNA in affected GM15850 cells.
  • Description
    A benzamide-type HDAC inhibitor with IC50 of 78 uM for changes of FXN mRNA in affected GM15850 cells; reverses FXN silencing in primary lymphocytes from individuals with Friedreich's ataxia; directly affects the histones associated with FXN, increasing acetylation at particular lysine residues on histones H3 and H4 (H3K14, H4K5 and H4K12); significantly improves motor performance, overall appearance, and body weight in an HD mouse model.
  • Synonyms
    NKL22;NKL-22
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    HDAC
  • Recptor
    HDAC
  • Research Area
    Other Indications
  • Indication
    ——

Chemical Information

  • CAS Number
    537034-15-4
  • Formula Weight
    325.40
  • Molecular Formula
    C19H23N3O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 29 mg/mL
  • SMILES
    O=C(NC1=CC=CC=C1N)CCCCCC(NC2=CC=CC=C2)=O
  • Chemical Name
    Heptanediamide, N1-(2-aminophenyl)-N7-phenyl-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Jia H, et al. Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):E56-64.
2. Thomas EA, et al. Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15564-9.
3. Herman D, et al. Nat Chem Biol. 2006 Oct;2(10):551-8.
molnova catalog
related products
  • Detomidine HCl

    Detomidine HCl produce dose-dependent sedative and analgesic effects, mediatated by activation of α2 catecholamine receptors.

  • BRD3308

    BRD3308 is a potent, selective HDAC3 inhibitor with IC50 of 54 nM.

  • Tasquinimod

    An orally active antiangiogenic agent with anti-prostate cancer activity, an allosteric modulator of HDAC4 with Kd of 10-30 nM.